In 2006, a veterinary manager examined a deceased mallard duck at a laboratory in Aberdeen, Scotland. Scientists studying pandemics are closely monitoring changes in the H5N1 bird flu virus.
In 2025, health experts are closely following several important stories that could shape our healthcare landscape. From the rising threat of bird flu to the growing use of drugs like Ozempic, here’s a look at the key issues that will dominate medical news in the year ahead.
H5N1 Bird Flu on the Radar
Health professionals continue to monitor the spread of the H5N1 strain of bird flu. The virus has already affected U.S. dairy cattle and devastated poultry farms in Canada. Recently, it was detected in ringed seals in Nunavut, and several human infections have been reported, although most cases have been mild. However, experts are concerned about the potential for the virus to mutate and spread easily between humans, which would present a major public health risk. There’s been growing concern after the virus jumped from infected birds to mammals, including mink, seals, and even domestic pets like dogs and cats. Health authorities are particularly focused on "reassortment events," where different strains of the flu virus mix, potentially creating a new version that humans have no immunity against.
Toxic Drug Crisis: A Glimmer of Hope
Canada's ongoing battle with toxic drugs is another critical issue to watch. While opioid-related deaths have shown a slight decline, the situation remains dire, with an average of 21 deaths per day. Political responses to the crisis, such as Ontario’s shutdown of supervised consumption sites and British Columbia’s push to recriminalize drug use in public, will likely continue to stir debate. Additionally, pilot projects offering safer drug supplies have shown promising results, with a significant reduction in overdose deaths in some areas. The national evaluation of these programs, set to release its findings in 2025, will shed light on whether safer supply measures can reduce harm and help curb the crisis.
Ozempic and the Rise of Weight Loss Medications
In the world of medication, the use of GLP-1 receptor agonists like Ozempic is soaring in Canada. These drugs, initially designed for diabetes management, have gained popularity as weight-loss treatments. According to recent data, there has been a 43% increase in people using weight-loss medications in the past year. This trend is expected to continue as pharmaceutical companies, such as Eli Lilly, aim to expand the use of these drugs beyond weight loss and diabetes to treat other conditions like alcohol and drug addictions, as well as inflammatory diseases. However, concerns about side effects such as nausea, muscle loss, and even severe conditions like pancreatitis are raising alarms among experts.
Long COVID and Its Lingering Effects
Long COVID remains a significant concern, with millions of Canadians still suffering from symptoms like fatigue, shortness of breath, and difficulty concentrating. This condition, which can last for months or even years, has left many individuals unable to work or care for their families, and the healthcare system is struggling to provide adequate support. As we enter 2025, the impact of long COVID on both individuals and the healthcare system will continue to be a major focus.
Vaccine Challenges and Progress
In 2025, Canada will review its National Immunization Strategy for the first time since 2016. The federal government is working to standardize vaccine data across provinces to improve tracking and vaccination coverage. But challenges remain, especially with the rise of vaccine skepticism in the U.S., where political figures like Robert F. Kennedy Jr. are questioning the safety of vaccines. These debates could influence public perception and policy in Canada as well.
Healthcare Funding and Access
With billions in additional funding from the federal government, Canadians will soon find out whether these investments in healthcare, including improving primary care access and mental health services, will lead to meaningful improvements. Reports from the Canadian Institute for Health Information will provide key insights into whether these new funds are helping to address long-standing challenges like wait times and access to healthcare providers.
